Management of patients with symptomatic SVT extension up to day 77 in the placebo group of the CALISTO study
| . | Placebo group (N = 1500) . | |
|---|---|---|
| Extension to ≤3 cm from the SFJ . | Extension to >3 cm from the SFJ . | |
| Treatment received during the study, no. (%) | ||
| Graduated compression stockings | 46 (3.1) | 51 (3.4) |
| Analgesic agents | 16 (1.1) | 22 (1.5) |
| Topical nonsteroidal antiinflammatory drugs | 17 (1.1) | 30 (2.0) |
| Topical anticoagulant drugs | 5 (0.3) | 8 (0.5) |
| Oral nonsteroidal antiinflammatory drugs/anti-cox 2 | 12 (0.8) | 13 (0.9) |
| Aspirin or other antiplatelet agents | 17 (1.1) | 15 (1.0) |
| Anticoagulant treatment* | 29 (1.9) | 30 (2.0) |
| High (therapeutic dose) | 19 (1.3) | 17 (1.1) |
| Intermediate dose | 1 (0.1) | 2 (0.1) |
| Low (prophylactic dose) | 14 (0.9) | 14 (0.9) |
| Unknown dose | 1 (0.1) | 1 (0.1) |
| Face-to-face visit after event diagnosis (in addition to those planned by the protocol), no. (%) | 34 (2.3) | 24 (1.6) |
| Compression ultrasonography to follow up this event after diagnosis, no. (%) | 19 (1.3) | 29 (1.9) |
| Hospitalization after event diagnosis, no. (%) | 33 (2.2) | 22 (1.5) |
| Duration, days (mean ± standard deviation) | 6.4 ± 6.3 | 6.6 ± 4.3 |
| Surgery to treat SVT, no. (%)† | 34 (2.3) | 20 (1.3) |
| No surgery to treat SVT, no. (%) | 19 (1.3) | 36 (2.4) |
| and no anticoagulant treatment either | 6 (0.4) | 14 (0.9) |
| . | Placebo group (N = 1500) . | |
|---|---|---|
| Extension to ≤3 cm from the SFJ . | Extension to >3 cm from the SFJ . | |
| Treatment received during the study, no. (%) | ||
| Graduated compression stockings | 46 (3.1) | 51 (3.4) |
| Analgesic agents | 16 (1.1) | 22 (1.5) |
| Topical nonsteroidal antiinflammatory drugs | 17 (1.1) | 30 (2.0) |
| Topical anticoagulant drugs | 5 (0.3) | 8 (0.5) |
| Oral nonsteroidal antiinflammatory drugs/anti-cox 2 | 12 (0.8) | 13 (0.9) |
| Aspirin or other antiplatelet agents | 17 (1.1) | 15 (1.0) |
| Anticoagulant treatment* | 29 (1.9) | 30 (2.0) |
| High (therapeutic dose) | 19 (1.3) | 17 (1.1) |
| Intermediate dose | 1 (0.1) | 2 (0.1) |
| Low (prophylactic dose) | 14 (0.9) | 14 (0.9) |
| Unknown dose | 1 (0.1) | 1 (0.1) |
| Face-to-face visit after event diagnosis (in addition to those planned by the protocol), no. (%) | 34 (2.3) | 24 (1.6) |
| Compression ultrasonography to follow up this event after diagnosis, no. (%) | 19 (1.3) | 29 (1.9) |
| Hospitalization after event diagnosis, no. (%) | 33 (2.2) | 22 (1.5) |
| Duration, days (mean ± standard deviation) | 6.4 ± 6.3 | 6.6 ± 4.3 |
| Surgery to treat SVT, no. (%)† | 34 (2.3) | 20 (1.3) |
| No surgery to treat SVT, no. (%) | 19 (1.3) | 36 (2.4) |
| and no anticoagulant treatment either | 6 (0.4) | 14 (0.9) |
Patients could have received more than 1 type or dosage regimen of anticoagulant treatment.
Patients with SVT to ≤3 cm from the SFJ: ligation of the sapheno-femoral or sapheno-popliteal junction in 31 and local thrombectomy in 3; patients with SVT to >3 cm from the SFJ: ligation of the sapheno-femoral or sapheno-popliteal junction in 18, local thrombectomy in 1, and varicose vein stripping within the great saphenous vein in 1.